Advances in Dermatology and Allergology
eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current Issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
6/2025
vol. 42
 
Share:
Send email
Share:
Original paper

Adverse reactions to intravenous immunoglobulin in primary immunodeficiency: a retrospective analysis

Fevzi Demirel
1
,
Fikriye Kalkan
2
,
Ali Selcuk
1
,
Sait Yesillik
1
,
Ozgur Kartal
1

  1. Department of Immunology and Allergy, University of Health Sciences, Gülhane Training and Research Hospital, Ankara, Türkiye
  2. Department of Immunology and Allergy, Ankara Bilkent City Hospital, Ankara, Türkiye
Adv Dermatol Allergol 2025; XLII (6): 572–578
DOI: https://doi.org/10.5114/ada.2025.158074
Online publish date: 2026/01/12
Article file
- Adverse reactions.pdf  [0.16 MB]
Get citation
 
 
1. Yazdani R, Habibi S, Sharifi L, et al. Common variable immunodeficiency: epidemiology, pathogenesis, clinical manifestations, diagnosis, classification, and management. J Investig Allergol Clin Immunol 2020; 30: 14-34.
2. Yazdani R, Abolhassani H, Asgardoon MH, et al. Infectious and noninfectious pulmonary complications in patients with primary immunodeficiency disorders. J Investig Allergol Clin Immunol 2017; 27: 213-24.
3. Ameratunga R, Allan C, Woon ST. Defining common variable immunodeficiency disorders in 2020. Immunol Allergy Clin North Am 2020; 40: 403-20.
4. Bousfiha A, Moundir A, Tangye SG, et al. The 2022 Update of IUIS phenotypical classification for human inborn errors of immunity. J Clin Immunol 2022; 42: 1508-20.
5. Bayry J, Ahmed EA, Toscano-Rivero D, et al. Intravenous immunoglobulin: mechanism of action in autoimmune and inflammatory conditions. J Allergy Clin Immunol Pract 2023; 11: 1688-97.
6. Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol 2018; 9: 1299.
7. Kareva L, Mironska K, Stavric K, Hasani A. Adverse reactions to intravenous immunoglobulins – our experience. Open Access Maced J Med Sci 2018; 6: 2359-62.
8. Antunes TS, Melo KM, Valente CFC, Tavares FS. Immediate adverse events to intravenous immunoglobulin in pediatric patients with inborn errors of immunity: a longitudinal study with a pre-infusion protocol. Hematol Transfus Cell Ther 2023; 45: 253-8.
9. Dashti-Khavidaki S, Aghamohammadi A, Farshadi F, et al. Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases. J Investig Allergol Clin Immunol 2009; 19: 139-45.
10. Esmaeilzadeh H, Askarisarvestani A, Hosseini N, et al. Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin. Clin Immunol 2021; 230: 108826.
11. Tcheurekdjian H, Martin J, Kobayashi R, et al. Intrainfusion and postinfusion adverse events related to intravenous immunoglobulin therapy in immunodeficiency states. Allergy Asthma Proc 2006; 27: 532-6.
12. Seidling V, Hoffmann JH, Enk AH, Hadaschik EN. Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events. Acta Derm Venereol 2013; 93: 346-9.
13. Aghamohammadi A, Farhoudi A, Nikzad M, et al. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency. Ann Allergy Asthma Immunol 2004; 92: 60-4.
14. Bichuetti-Silva DC, Furlan FP, Nobre FA, et al. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions. Int Immunopharmacol 2014; 23: 442-6.
15. Lozeron P, Not A, Theaudin M, et al. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease. Muscle Nerve 2016; 53: 683-9.
16. Souayah N, Hasan A, Khan HM, et al. The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders. J Clin Neuromuscul Dis 2011; 12 Suppl 4: S1-10.
17. Manlhiot C, Tyrrell PN, Liang L, et al. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content. Pediatrics 2008; 121: e626-30.
18. Cornblath DR, van Doorn PA, Hartung HP, et al. Safety and tolerability of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: results of the ProCID Study. Drug Saf 2023; 46: 835-45.
19. Hasırcı Bayır BR, Ünsal MA, Ağırcan C, et al. IVIg-induced headache: prospective study of a large cohort with neurological disorders. Neurol Sci 2023; 44: 2871-81.
20. Nain E, Kıykım A, Kasap NA, et al. Immediate adverse reactions to intravenous immunoglobulin in primary immune deficiencies: a single center experience. Turk J Pediatr 2020; 62: 379-86.
21. Taha SA, Thalappil S, Ali RM, et al. Intravenous immunoglobulin therapy: usage patterns and response to treatment in Qatar over ten years. Front Immunol 2024; 15: 1481079.
22. Williams SJ, Gupta S. Anaphylaxis to IVIG. Arch Immunol Ther Exp 2017; 65: 11-9.
23. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol 2017; 139: S1-46.
24. Rachid R, Castells M, Cunningham-Rundles C, Bonilla FA. Association of anti-IgA antibodies with adverse reactions to -globulin infusion. J Allergy Clin Immunol 2011; 128: 228-30.e1.
25. Horn J, Thon V, Bartonkova D, et al. Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin Immunol 2007; 122: 156-62.
26. Kemmotsu Y, Nakayama T, Matsuura H, Saji T. Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with Kawasaki disease. Pediatr Rheumatol Online J 2011; 9: 28.
27. Bharath V, Eckert K, Kang M, et al. Incidence and natural history of intravenous immunoglobulin-induced aseptic meningitis: a retrospective review at a single tertiary care center. Transfusion 2015; 55: 2597-605.
28. Borte M, Hanitsch LG, Mahlaoui N, et al. Facilitated subcutaneous immunoglobulin treatment in patients with immunodeficiencies: the FIGARO study. J Clin Immunol 2023; 43: 1259-71.
29. Erbas Acici N, Topyildiz E, Aygun A, et al. Facilitated subcutaneous immunoglobulin treatment increases the quality of life and decreases the number of infections and hospitalizations in children with primary immunodeficiencies. Int Arch Allergy Immunol 2024; 185: 382-91.
30. Kose S, Sabetsarvestani R, Geckil E, et al. The experiences of children with primary immunodeficiency who receive immunoglobulin subcutaneously instead of intravenously. J Pediatr Health Care 2024; 38: 13-20.
31. Yori S, Belleri F, Testard J, et al. Intravenous immunoglobulin G use and pharmacovigilance in a tertiary care children’s hospital. Arch Argent Pediatr 2021; 119: 192-7.
32. Jiang M, Kimber JS, Gupta A, et al. Adverse reactions associated with intravenous immunoglobulin administration in the treatment of neurological disorders: a systematic review. Int Arch Allergy Immunol 2023; 184: 513-28.
33. Côté J, Chaloult-Lavoie M, Poulin É, et al. Incidence of adverse events related to intravenous immunoglobulin therapy in children. Transfusion 2025; 65: 88-99.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2026 Termedia Sp. z o.o.
Developed by Bentus.